Celldex Therapeutics (CLDX)
NASDAQ:CLDX
Top Page
Celldex
(NASDAQ:CLDX)
Select Model
Select Model
Rating:56Neutral
Price Target:
$32.00
▼(-4.82% Downside)
Action:ReiteratedDate:04/03/26
The score is held back primarily by weak financial performance—large losses and rising cash burn—despite a low-debt balance sheet. Technicals are supportive with an uptrend and positive momentum, while valuation is constrained by ongoing unprofitability. The equity offering improves funding runway but adds dilution risk.
Positive Factors
Low leverage balance sheet
Very low reported debt materially reduces refinancing and solvency risk, giving Celldex durable financial flexibility to support multi-year clinical development. This structural balance-sheet strength lowers short-term default risk and helps preserve options for partnering or selective investment despite ongoing operating losses.
Negative Factors
Accelerating cash burn
Consistently large and rising negative cash flows necessitate ongoing external financing to sustain development and commercialization activities. Persistent cash burn increases reliance on capital markets, limits strategic optionality, and elevates the risk that dilution or funding gaps will impair long-term program execution.
Read all positive and negative factors
Positive Factors
Negative Factors
Low leverage balance sheet
Very low reported debt materially reduces refinancing and solvency risk, giving Celldex durable financial flexibility to support multi-year clinical development. This structural balance-sheet strength lowers short-term default risk and helps preserve options for partnering or selective investment despite ongoing operating losses.
Read all positive factors
Celldex (CLDX) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$2.24B
Dividend YieldN/A
Average Volume (3M)1.22M
Price to Earnings (P/E)―
Beta (1Y)1.16
Revenue Growth-73.94%
EPS Growth-31.70%
CountryUS
Employees186
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-1.22
Shares Outstanding66,566,345
10 Day Avg. Volume1,486,107
30 Day Avg. Volume1,219,906
Financial Highlights & Ratios
PEG Ratio-0.12
Price to Book (P/B)3.43
Price to Sales (P/S)1204.09
P/FCF Ratio-8.45
Enterprise Value/Market Cap0.99
Enterprise Value/Revenue1.47K
Enterprise Value/Gross Profit1.47K
Enterprise Value/Ebitda-7.95
Forecast
1Y Price Target
$54.50Price Target Upside62.11% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering11
EPS Forecast (FY)-4.83
Revenue Forecast (FY)$2.85M
Celldex Business Overview & Revenue Model
Company Description
Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with i...
How the Company Makes Money
Celldex does not have a broad, recurring commercial product revenue base; as a clinical-stage biotech, it primarily funds operations through external financing (e.g., issuing equity and, when applicable, other capital-raising activities). Revenue,...
Celldex Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
72
Positive
Cash Flow
34
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 1.50M | 7.02M | 6.88M | 2.36M | 4.65M |
| Gross Profit | 1.50M | -156.53M | -111.13M | -79.90M | -48.66M |
| EBITDA | -255.42M | -191.90M | -139.03M | -104.20M | -66.08M |
| Net Income | -258.80M | -157.86M | -141.43M | -112.33M | -70.51M |
Balance Sheet | |||||
| Total Assets | 582.98M | 792.34M | 465.63M | 352.74M | 444.65M |
| Cash, Cash Equivalents and Short-Term Investments | 518.57M | 725.28M | 421.70M | 304.95M | 408.25M |
| Total Debt | 2.34M | 3.81M | 2.54M | 4.03M | 3.04M |
| Total Liabilities | 55.82M | 45.34M | 36.46M | 26.53M | 25.18M |
| Stockholders Equity | 527.16M | 747.00M | 429.17M | 326.20M | 419.48M |
Cash Flow | |||||
| Free Cash Flow | -213.66M | -159.70M | -109.11M | -105.56M | -62.16M |
| Operating Cash Flow | -210.94M | -157.78M | -107.29M | -103.73M | -60.91M |
| Investing Cash Flow | 209.07M | -290.13M | -105.78M | 89.94M | -216.16M |
| Financing Cash Flow | 2.39M | 441.45M | 218.46M | 4.08M | 272.37M |
Celldex Technical Analysis
Positive
33.62
Price Trends
28.13
Positive
27.35
Positive
25.64
Positive
Market Momentum
1.04
Negative
65.83
Neutral
86.30
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CLDX, the sentiment is Positive. The current price of 33.62 is above the 20-day moving average (MA) of 30.88, above the 50-day MA of 28.13, and above the 200-day MA of 25.64, indicating a bullish trend. The MACD of 1.04 indicates Negative momentum. The RSI at 65.83 is Neutral, neither overbought nor oversold. The STOCH value of 86.30 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for CLDX.
Celldex Risk Analysis
Celldex disclosed 2 risk factors in its most recent earnings report. Celldex reported the most risks in the "Legal & Regulatory" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Celldex Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
56 Neutral | $2.24B | ― | -41.68% | ― | -73.94% | -31.70% | |
54 Neutral | $1.57B | -5.48 | -58.44% | ― | 23340.07% | 18.06% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | $883.88M | -7.53 | -11.55% | ― | -23.37% | -42.45% | |
48 Neutral | $2.92B | -10.86 | -59.72% | ― | ― | -53.44% | |
47 Neutral | $2.90B | -67.82 | -79.16% | ― | 114.22% | 77.02% |
* Healthcare Sector Average
CLDX
Celldex
33.62
17.68
110.92%
TVTX
Travere Therapeutics
31.44
17.95
133.06%
VRDN
Viridian Therapeutics
15.38
3.97
34.79%
VERA
Vera Therapeutics
40.93
19.12
87.67%
JANX
Janux Therapeutics Inc
14.53
-12.34
-45.92%
Celldex Corporate Events
Business Operations and StrategyPrivate Placements and Financing
Celldex Announces Major Underwritten Public Equity Offering
Positive
Apr 2, 2026
On April 1, 2026, Celldex Therapeutics entered an underwriting agreement with Leerink Partners and TD Securities for an underwritten public offering of 10,345,000 shares of common stock at $29.00 per share, expected to raise about $282 million in ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.